

Long-term Results of Correction of High Myopia With an Iris Claw Phakic Intraocular Lens

Monika Landesz, MD; J.G.F. Worst, MD; Gabriel van Rij, MD, PhD

ABSTRACT

PURPOSE: Anterior chamber phakic intraocular lenses (PIOLs) are one of the modalities used to correct high myopia. We report the long-term results of our prospective study on the Artisan 5-mm optic myopia lens.

METHODS: We studied 67 eyes of 38 consecutive patients with preoperative myopia ranging from -5.38 to -28.00 D. All patients were operated by one surgeon. Mean follow-up was 35 months (24 months in 67 eyes and 36 months in 61 eyes).

RESULTS: In 45 eyes (67.2%), postoperative residual refraction was within ± 1.00 D of emmetropia. The mean refraction was stable statistically during the entire follow-up period. Mean best spectacle-corrected visual acuity improved from 20/40 to 20/32. Mean endothelial cell loss at 6 months was 5.5% (range, -52.4% to +9.3%), at 12 months, 7.21% (range, -53.2% to +20.1%), at 24 months, 9.1% (range -43.6% to +13.6%), and at 36 months, 10.9% (range, -43.0% to +11.4%). The majority of eyes had an increase in best spectacle-corrected visual acuity; 5 eyes lost best spectacle-corrected visual acuity. We encountered no major complications.

CONCLUSION: Implanting the Artisan 5-mm optic myopia lens in high myopic eyes resulted in a stable and accurate refractive outcome. The apparent progressive corneal endothelial cell loss remains a matter of concern. [*J Refract Surg* 2000;16:310-316]

Over the last few years, phakic anterior chamber lenses for correction of high myopia have been implanted with satisfactory refractive results.¹⁻⁴ In 1986, Worst and Fechner modified the existing iris claw lens for aphakia (used in cataract surgery) into a negatively biconcave lens, to be used in high myopic phakic eyes. This new Worst-Fechner lens had an optic diameter of 4.5 mm, and a few hundred of these lenses were implanted with good refractive results.⁵⁻¹⁰ To increase the safety of this phakic intraocular lens (PIOL), the optical part was altered into a convex-concave shape in 1991 and the diameter of the optical part was increased to 5.0 mm, to reduce halos and glare. This new lens, called the Worst myopia claw lens, has been implanted successfully ever since.^{11,12} In 1998, the name of the lens was changed to the Artisan myopia lens, without a change in lens design; it still has a convex-concave optical part. It is also available in 6-mm diameter for all powers up to -15.50 diopters (D). In 1995, we published the preliminary results of our prospective study on the implantation of the convex-concave 5-mm diameter Worst myopia claw lens in high myopes.¹¹ Because most of these patients have now been followed for 3 years, we present current results.

PATIENTS AND METHODS

Patients

This prospective study consists of consecutive cases operated in Stadskanaal, The Netherlands, by the same experienced surgeon (JGFW). Patients were sent to the Department of Ophthalmology at the University Clinic in Groningen for independent preoperative and postoperative examinations. Each patient was informed of the investigative nature of the procedure and received a detailed oral and written informed consent, in accordance with the

From the Department of Ophthalmology, University Hospital Rotterdam, The Netherlands (Landesz and van Rij) and Refaja Hospital Stadskanaal, The Netherlands (Worst).

Authors M. Landesz and G. van Rij have no financial interest in the lens described. J.G.F. Worst has a financial interest in the lens described.

Correspondence: M. Landesz, MD, Oog Chirurgisch Centrum Rotterdam Airport, Vliegvelddweg 65, 3043 NT Rotterdam, The Netherlands. Tel: 31.10.2989897; Fax: 31.10.2989890; E-mail: info@pointofvision.nl

Received: July 16, 1999

Accepted: March 17, 2000

Table 1
Refraction in 67 Eyes Before
Implantation of Artisan Anterior
Chamber PIOL

No. Eyes (n=67)	Refraction (D)
15	-5.38 to -10.00
26	-10.12 to -15.00
19	-15.12 to -20.00
7	-20.12 to -28.00

Helsinki Declaration. The study was approved by the medical ethics board of Refaja Hospital in Stadskanaal.

A total of 73 eyes of 38 patients were operated, but for this report we excluded patients who were lost to follow-up early in the study. Therefore, the final study group was comprised of 67 eyes (92% of the original population) of 36 patients (95%; 20 men and 16 women). Patient age ranged from 17 to 52 years (mean, 35.4 ± 9.7 yr). Preoperative refraction ranged from -5.40 to -28.00 D, of which the majority had myopia between -10.12 and -20.00 D (Table 1). The follow-up period was 24 months in 67 eyes and 36 months in 61 eyes (86%).

Artisan Myopia Claw Lens

The convex-concave Artisan myopia lens used in this study is made of one-piece clinical quality ultraviolet absorbing polymethylmethacrylate, and is manufactured by OPHTEC B.V. in Groningen, The Netherlands. For any amount of correction, the total length of the lens used in this study was 8.5 mm with an optic 5 mm in diameter. The vault height of the lens did not exceed 0.96 mm, regardless of its power. The lens power at the time the patients were operated ranged from -5.00 to -20.00 D and was manufactured in steps of 1.00 D. The two diametrically opposed haptics fixated the lens on the iris by enclavation of midperipheral iris stroma.

Surgical Technique and Medication

For more details about the surgical technique, we refer to a publication in 1998.¹³ In short, the technique consisted of a corneoscleral incision of 6 mm at 12 o'clock. The anterior chamber was filled with a viscoelastic substance, sodium hyaluronate (Healon, Kabi Pharmacia, Stockholm, Sweden) before implanting the lens. The lens was inserted in the anterior chamber with a special implantation forceps and was then released. The lens was rotated into the horizontal position, bringing the enclavation sites to 3 and 9 o'clock. Small folds of iris tissue were enclavated with the iris "crochet" needle.

Subsequently, a peripheral iridectomy was performed. All viscoelastic material was removed carefully with balanced salt solution, after which the incision was closed with 6 to 8 interrupted stainless steel sutures, the surgeon's (JGFW) preferred suture material.

Gentamicin 40 mg with betamethasone 4 mg was injected subconjunctivally immediately after surgery. Postoperatively, tropicamide 1% eye drops and acetazolamide 250 mg tablets were administered in the first two days, timolol 0.5%, and cyclopentolate 1% during the first week, and prednisolone, neomycin, and indomethacin topically during the first 5 weeks.

Clinical Examination

Preoperatively, all eyes were examined by slit-lamp microscopy and funduscopy to exclude any ocular disease, especially glaucoma and maculopathies. Patients with autoimmune disease were excluded. To determine the power of the PIOL, we measured the subjective refraction, the corneal curvature with the Zeiss keratometer, and the anterior chamber depth with ultrasound.

These three parameters were used in the Van der Heijde formula.¹⁴ To determine the predictability of the refractive outcome we converted the Van der Heijde formula in such a way that we could calculate the expected correction for each implantation preoperatively. For measurement of visual acuity, we used the modified Bailey-Lovie chart, placed in a box with standardized direct illumination.¹⁵ The visual acuity was expressed in the logarithm of the minimal angle of resolution (logMAR) and was converted into Snellen notation.

For examination of the corneal endothelium, we used a Zeiss non-contact specular microscope in 7 eyes and a Keeler Konan sp-3300 wide-field contact specular microscope in all other eyes, in combination with a video camera and a frame grabber. Because of technical difficulties later in the study, all eyes were examined with a noncontact autofocus camera, Konan Noncon Robo-ca sp 8000, from the beginning of 1995. We adjusted the outcome for the difference compared with the other cameras.¹⁶ Three images were made of each eye during each session and were processed. The weighted average of the three processed images are presented as the mean endothelial cell density.

Follow-up examinations were done at 24 hours, 1 week, 2 to 4 weeks, 2 to 4 months, 6 months, and 12 months. After that, patients were examined annually. Patients with complications were examined more frequently. Specular microscopy was

Table 2
Refractive Outcome in 67 Eyes After
Implantation of Artisan Anterior
Chamber PIOL

Spherical Equivalent Refraction (D)	No. Eyes With Residual Refractive Error	No. Eyes With a Difference From Calculated Outcome
> +3.10	0	0
+2.12 to +3.00	1	0
+1.12 to +2.00	2	2
+1.00 to +0.62	1	9
+0.50 to +0.12	6	13
-0.50 to -0.00	26	9
-0.51 to -1.00	12	8
-1.12 to -2.00	8	9
-2.12 to -3.00	5	5
> -3.00	6	2

performed after 2 to 4 months, at 6 and 12 months, and then annually. Postoperative examinations included slit-lamp microscopy, applanation tonometry, manifest refraction, and best spectacle-corrected and uncorrected visual acuity.

All patients were asked to respond subjectively about satisfaction with their visual outcome. Statistical calculations were performed with SPSS 8.0 for Windows. A two-tailed probability of 0.05 or less was considered statistically significant.

RESULTS

Refraction and Visual Acuity

Mean spherical equivalent refraction was -14.70 ± 4.90 D preoperatively, -0.79 ± 2.20 D after 6 months, -0.92 ± 2.30 D after 12 months, -1.12 ± 2.10 D after 24 months, and -1.05 ± 2.20 D after 36 months. In Figure 1, we show individual refractive outcome in a scattergram. In 45 eyes (67.2%), postoperative spherical equivalent residual myopia was within ± 1.00 D of emmetropia (Table 2). Undercorrection exceeding 2.00 D occurred in 11 eyes (16.4%); in 1 eye an overcorrection of more than 2.00 D was observed.

In Figure 2, we plotted the time course of the mean postoperative refraction. The analysis of variance (ANOVA) test did not show any significant differences over time ($P = .12$). In 7 eyes, the postoperative refraction changed by 1.00 D or more. In one eye, a severe change in refraction was due to the development of a nuclear cataract.

Figure 3 shows deviation of achieved correction from calculated correction for each eye. The mean deviation of refractive outcome was -0.16 D (range,




Figure 1. Postoperative refraction at the last follow-up examination after implantation of Artisan myopia PIOL. (X-axis orientation: numbers go from largest to smallest, left to right.)




Figure 2. Time course of postoperative refraction over a 3-year follow-up period after implantation of Artisan myopia PIOL. (SD at 6 mo, 2.20 D; at 12 mo, 2.30 D; at 24 mo, 2.10 D; at 36 mo, 2.20 D.)

-5.18 to $+2.82$ D). The difference around the calculated outcome was within ± 1.00 D in 39 eyes (58.0%) (Table 2). The 95% confidence interval of deviation in predicted outcome was between -0.51 and $+0.19$ D.

Mean spectacle-corrected visual acuity for all eyes improved from 20/40 preoperatively to 20/32 postoperatively. Mean postoperative uncorrected visual acuity was 20/50. The cumulative number of eyes with an uncorrected visual acuity of 20/20 or better was 8 (12.1%), 20/25 or better in 10 eyes (15.2%), 20/30 or better in 22 eyes (33.3%), and 20/40 or better in 27 eyes (40.9%). Spectacle-corrected visual acuity was 20/20 or better in 16 eyes (23.9%), 20/25 or better in 28 eyes (53.7%), 20/30 or better in 52 eyes (77.6%), and 20/40 or better in 55 eyes (82.1%).

Change in best spectacle-corrected visual acuity showed an increase of one Snellen line or more in




Figure 3. Deviation from attempted correction in eyes after implantation of Artisan myopia PIOL. (X-axis orientation: numbers go from largest to smallest, left to right.)




Figure 4. Change in best spectacle-corrected visual acuity after implantation of Artisan myopia PIOL.

the majority of the eyes (Fig 4). In 5 eyes, we observed a loss of best spectacle-corrected visual acuity by one line or more. In two eyes this was due to cataract formation. In the remaining eyes, we could not find a cause.

Corneal Endothelium

Figure 5 shows the mean corneal endothelial cell loss over the entire follow-up period. We corrected the measured cell loss with the predicted cell loss from aging—0.6% per year.¹⁷ The mean cell loss in all 67 eyes was 5.5% at 6 months (range, -52.4% to +9.3%), 7.2% at 12 months (range, -53.2% to +20.1%), 9.1% at 24 months (range, -43.6% to +13.6%), and 10.9% at 36 months (range, -43.0% to +11.4%). The cell loss during the entire 3-year follow-up period is statistically significantly progressive (ANOVA, $P = .0001$).

The mean anterior chamber depth of these 67 eyes was 3.7 mm (range, 3.1 to 4.3 mm). We did not find any correlation between the anterior chamber depth and the amount of cell loss. Because 23 patients wore contact lenses previously, we tested to determine if the cell loss was significantly different. At 36 months, mean cell loss in contact lens wearers was 11.0% (range, -43.0 to +11.4%), and in non-contact lens wearers 9.9% (range, -24.7% to +5.1%), which was not significantly different (Student's t -test, $P = .63$).

Complications

Examination by slit-lamp microscopy revealed no apparent flare in the anterior chamber, nor did we see damage to the iris tissue. During surgery, we




Figure 5. Mean endothelial cell loss after implantation of Artisan myopia PIOL, corrected for mean cell loss due to aging of 0.6% per year. (SD at 6 mo, 9.1%; at 12 mo, 10.2%; at 24 mo, 8.9%; at 36 mo, 8.6%.)

noticed corneal endothelial touch in one eye. The preoperative cell count was 2851 cells/mm² and the postoperative cell count was 1351 cells/mm² at 12 months, 1571 cells/mm² at 24 months, and 1569 cells/mm² at 36 months—a surgically induced and stable cell loss.

In one eye the PIOL had to be recentered 4 months after surgery because of distorted images. Unfortunately, we could not perform endothelial cell counting prior to the second surgical intervention, but the mean endothelial cell densities preoperatively and 36 months postoperatively were 3274 cells/mm² and 2441 cells/mm², respectively.

One patient had a blunt trauma to his left eye 4.5 months after surgery, without any obvious ocular damage. The endothelial cell counts in this eye

were 3751 cells/mm² preoperatively, 3385 cells/mm² after 6 months, 3332 cells/mm² after 12 months, 3190 cells/mm² after 24 months, and 3025 cells/mm² after 36 months.

In the left eye of another patient a severe inflammatory reaction in the anterior chamber was observed during the early postoperative period, which disappeared during the first week after medical treatment. The mean endothelial cell loss at 24 months in this patient was 19.2%. One patient had increased postoperative intraocular pressure in both eyes of 26 and 28 mmHg, which normalized after treatment and discontinuation of topical corticosteroids. One patient, 50 years old, developed a nuclear cataract 3 years after surgery in both eyes.

In total, 8 patients (22.2%) complained of seeing halos at night. Two of these patients were disturbed by this enough that they sometimes use pilocarpine 0.5% at night. Only one patient complained of glare. In general, the patients were very satisfied with the results. On a scale of 1 to 10 (1—very poor, and 10—excellent), the mean satisfaction score for visual outcome in these patients was 7.9 (range, 5 to 10).

DISCUSSION

There are a variety of surgical procedures to treat high myopia. Sophisticated keratorefractive surgical techniques to correct high myopia, such as epikeratoplasty, keratomileusis, and excimer laser photorefractive keratectomy (PRK), have shown unpredictable results in refractive outcome, refractive regression, and even scar formation.^{3,4} The results of LASIK seem promising¹⁸⁻²⁰, but correcting high myopia gives unsatisfactory results.²¹ Clear lensectomy to correct high myopia is another surgical modality, but is still considered controversial^{22,23}, due to the increased incidence of retinal detachment in patients with high myopia. The incidence of retinal detachment in different studies on clear lens extraction varies between 1.9%²² and 7.3%.²³ Another problem with this type of surgery is the development of posterior capsule opacification, which was described in 36.7%²³ of eyes, and the loss of accommodation in young patients. *

The use of PIOLs in high myopia has a well-defined advantage over corneal procedures in terms of refractive outcome. The high percentage of achieved near-emmetropia, as well as accuracy, stability, and predictability of refractive outcome, confirm findings of other investigations on phakic anterior chamber lenses.⁴⁻¹³ These results support the use of PIOLs for the correction of moderate to high refractive errors. However, the potential risks of

these lenses need to be evaluated before using them on a large scale.

The surgeon (JGF Worst) in this study had much experience in implanting the claw lens in aphakia, the biconcave Worst-Fechner PIOL, and the Artisan myopia lens, so there was no learning curve that could influence the results on the effect on the corneal endothelium. In our population group the mean endothelial cell loss was 5.5% after 6 months, 7.12% after 1 year, 9.1% after 2 years, and 10.9% after 3 years. There seems to be progressive endothelial cell loss, therefore we want to follow these patients for a longer period of time to examine whether cell loss will stabilize after 3 years, as was seen in a long-term study on phacoemulsification.²⁴ However, because we were forced to use different techniques for endothelial cell counting, these results might not be as accurate. A study by Menezo and colleagues²⁵ on both the biconcave Worst-Fechner and the convex-concave Artisan myopia lenses together showed a cell loss of 7.9% at 1 year, 11.8% at 2 years, 13.4% at 3 years, 15.8% at 4 years, and 17.9% at 5 years. It is not clear whether the natural aging of the endothelium was taken into account in this study. In a study on the biconcave Worst-Fechner lens^{8,9}, severe endothelial cell loss was encountered in three eyes that subsequently required corneal transplantation. Certain studies on angle-supported phakic anterior chamber lenses reported a marked decrease in cell density after 1 year with a mean cell loss of 16.6%, ranging from 0 to 53.2%.^{26,27} However, Baikoff and colleagues²¹ observed a cell loss of 4.5% at 1 year and 5.5% at 3 years in patients with a newer type of angle-supported PIOL. Another study²⁹ on this type of lens showed a cell loss of 7.5% at 3 years with a progressive cell loss that varied between 0.3% to 0.6% yearly, up to 7 years postoperative.

Although we did not detect flare in our patients by microscopy, anterior chamber lenses may lead to important blood-aqueous-barrier changes due to the fixation on the iris or pressure of the footplates on the iris root. This can produce subclinical uveitis, which may cause chronic endothelial cell loss.³⁰ Nonetheless, a retrospective study³¹ on the protein and the cell concentrations in the anterior chamber of eyes with a biconcave Worst-Fechner lens did not show a significantly raised protein concentration or elevated concentrations of cells. Iris angiography on a subgroup of patients with an Artisan myopia lens¹² did not show any leakage in the anterior chamber. Because we could not perform laser flare photometry, the concern about an ongoing

inflammatory response creating chronic progressive endothelial cell loss in these phakic anterior chamber lenses^{30,32} can only be excluded in our patient population by a long-term study on the endothelium.

Damage to the iris has been described in both iris-fixated and angle-supported PIOLs. In our study, we have not noticed any sign of iris atrophy or other abnormalities at the enclavation sites. However, others²⁵ reported iris damage in 4.2% of 94 eyes. Several authors^{26,29} have described specific complications in patients with an angle-supported lens, such as inflammatory reactions, pupillary deformations, iris atrophy, iris perforation, and adherence of the iris to the footplate. Complications that have been described in iris-fixated PIOLs are early postoperative iritis, iridocyclitis, cystic wounds, temporary increased intraocular pressure, and Urrets-Zavalía syndrome.^{4,8,9} An early postoperative inflammatory reaction happened in only one eye of our series. None of the other problems described above have occurred in our patient group. The use of an iridectomy or iridotomy in this type of lens is highly recommended.

Elevated intraocular pressure and pupillary block due to the configuration of the different PIOLs are other possible complications. Only one patient in our study had transient raised intraocular pressure in both eyes in the immediate postoperative period that normalized after discontinuation of topical corticosteroids. The percentage of raised intraocular pressure in other studies was 5.3%²⁵ and 16%.⁸ Studies on the angle-supported and posterior chamber PIOL describe increased intraocular pressure in 7.2%²⁹ and pupillary block in 4.8%³³ of cases.

We do not think that the nuclear cataract that developed in one patient after 3 years can be ascribed to the PIOL itself, because there was no opacification of the anterior capsule, nor did we see cataract formation in the other eyes. One can imagine that during implantation, the anterior capsule of the crystalline lens might have been touched by the intraocular lens. In a study by Menezo and colleagues²¹ on the Artisan myopia lens, no cataract formation was noticed.

High myopia may cause blinding complications, even when these eyes are not operated. One of the serious complications that has been related to phakic anterior chamber lenses is retinal detachment; the exact incidence and prevalence of retinal detachment is unknown. An incidence up to 0.8%^{9,9} was reported when using the iris-fixated type of PIOL. With other models of PIOLs, retinal detachment has

been reported in 0.8%³¹, and 0.6%⁴ of cases. An expectation of 4.5% of retinal detachment in angle-supported lenses at 79 months was described in another study.²⁹ In our group of 67 eyes, we have not encountered a retinal detachment in 3 years, nor did Menezo and coworkers²⁵ in their study of 94 eyes up to 72 months postoperative.

Night halos and glare were reported in 25% of our patients. Only three patients (8.3%) were significantly hindered by halos, and two of these patients use pilocarpine on occasion. A perfect lens centration of the Artisan myopia lens is technically difficult because it involves good enclavation of the iris on both sides. We think that when the lens is slightly decentered toward 12 o'clock, patients experience more halos or glare. Also, large pupil sizes can be responsible for these visual effects at night. To diminish these problems, the optical part of the lens has been enlarged to 6 mm in diameter for lenses up to a power of -15.00 D, since 1998.

Our study supports the satisfactory refractive outcome of phakic anterior chamber lenses in terms of predictability and stability. Of course, the main study subject of this procedure is its safety. The technique remains an intraocular surgical procedure with potential risks. In our series, no major complication occurred, nor did we have to explant any of the lenses. Patients will be followed as long as possible and we hope to report 5-year data.

REFERENCES

1. Barraquer J. Anterior chamber plastic lenses. Results of and conclusions from five years experience. *Trans Ophthalmol Soc UK* 1959;79:393-242.
2. Choyce PD. The correction of high myopia. *J Refract Corneal Surg* 1992;8:242-245.
3. Baikoff GB, Joly P. Comparison of minus power anterior chamber intraocular lenses and myopic epikeratoplasty in phakic eyes. *Refract Corneal Surg* 1990;6:252-260.
4. Colin J, Mimouni F, Robinet A, Conrad H, Mader P. The surgical treatment of high myopia: comparison of epikeratoplasty, keratomileusis and minus power anterior chamber lenses. *Refract Corneal Surg* 1990;6:245-251.
5. Fechner PU, van der Heijde GL, Worst JGF. Intraokulare Linse zur Myopiekorrektion des phaken Auges. *Klin Mbl Augenheilk* 1988;193:29-34.
6. Fechner PU, Worst JGF. A new concave intraocular lens for the correction of high myopia. *Eur J Implant Refract Surg* 1989;1:41-43.
7. Fechner PU, van der Heijde GL, Worst JGF. The correction of myopia by lens implantation into phakic eyes. *Am J Ophthalmol* 1989;197:659-663.
8. Fechner PU, Strabel J, Wichmann W. Correction of myopia by implantation of a concave Worst iris claw lens into phakic eyes. *J Refract Corneal Surg* 1991;7:286-298.
9. Fechner PU, Wichmann W. Correction of myopia by implantation of minus optic (Worst Iris Claw) lenses into the anterior chamber of phakic eyes. *Eur J Implant Refract Surg* 1993;5:55-59.
10. Worst JGF, van der Veen G, Los L. Refractive surgery for high myopia. The Worst-Fechner biconcave iris claw lens. *Documenta Ophthalmologica* 1990;75:335-354.

Long-term Results of Correction of High Myopia with an Iris Claw IOL/Landesz et al

11. Landesz M, Worst JGF, Siertsema JV, van Rij G. Correction of high myopia with the Worst myopia claw intraocular lens. *J Refract Surg* 1995;11:16-25.
12. Menezo JL, Cisneros A, Hueso JR, Harto M. Long-term results of surgical treatment of high myopia with Worst-Fechner intraocular lenses. *J Cataract Refract Surg* 1995;21:93-98.
13. Worst JGF, Landesz M. Phakic iris-supported lenses for the correction of high myopia and hyperopia. *Operative Techniques in Cataract and Refractive Surgery*. 1998;1:147-156.
14. Van der Heijde GL. Some optical aspects of implantation of an IOL in a myopic eye. *Eur J Implant Refract Surg* 1989;1:245-248.
15. Ferris LR, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. *Am J Ophthalmol* 1982;94:91-96.
16. Landesz M, Siertsema JV, van Rij G. Comparative study of three different semiautomated specular microscopes. *J Cataract Refract Surg* 1995;21:409-416.
17. Bourne WM, Nelson LR, Hodge DO. Central corneal endothelial cell changes over a ten-year period. *Invest Ophthalmol Vis Sci* 1997;38:779-782.
18. Buratto L, Ferrari M. Photorefractive keratectomy or keratomileusis with excimer laser in surgical correction of severe myopia: which technique is better? *Eur J Implant Refract Surg* 1993;5:183-186.
19. Siganos DS, Pallikaris IG. Laser in situ keratomileusis in partially sighted eyes. *Invest Ophthalmol Vis Sci* 1993;34:800.
20. Buratto L, Ferrari M, Genisi C. Myopic keratomileusis with the excimer laser: one-year follow-up. *Refract Corneal Surg* 1993;9:12-19.
21. Knorz M, Liermann A, Seiberth V, Steiner H, Wiesinger B. Laser in situ keratomileusis to correct myopia of -6 to -29 diopters. *J Refract Surg* 1996;12:575-584.
22. Colin J, Robinet A. Clear lensectomy and implantation of a low-power posterior chamber intraocular lens for correction of high myopia. A four-year follow-up. *Ophthalmology* 1997;104:73-78.
23. Barraquer C, Cavaliar C, Mejia LF. Incidence of retinal detachment following clear lens extraction in myopia patients. Retrospective analysis. *Arch Ophthalmol* 1994;112:336-339.
24. Werblin FP. Long-term endothelial cell loss following phacoemulsification: model for evaluating endothelial damage after intraocular surgery. *Refract Corneal Surg* 1993;9:29-35.
25. Menezo JL, Avino JA, Cisneros A, Rodriguez-Salvador V, Martinez-Costa R. Iris claw phakic intraocular lens for high myopia. *J Refract Surg* 1997;13:545-555.
26. Mimouni F, Colin J, Koffi V, Bonnet P. Damage to the corneal endothelium from anterior chamber intraocular lenses in phakic myopic eyes. *Refract Corneal Surg* 1991;7:277-281.
27. Saragoussi JJ, Cotinat J, Renard G, Savoldelli M, Abenheim A, Pouliquen Y. Damage to the corneal endothelium by minus power anterior chamber intraocular lenses. *Refract Corneal Surg* 1991;7:282-285.
28. Baikoff G, Arne JL, Bokobza Y, Colin J, George JL, Lagoutte F, Lesure P, Montard M, Saragoussi JJ, Secheyron P. Angle-fixated anterior chamber phakic intraocular lens for myopia of 7 to 19 diopters. *J Refract Surg* 1998;14:282-293.
29. Alio JL, de la Hoz F, Perez-Santonja JJ, Ruiz-Moreno JM, Quesada JA. Phakic anterior chamber lenses for the correction of myopia: a 7-year cumulative analysis of complications in 263 cases. *Ophthalmology* 1999;106:458-466.
30. Alio JL, de la Hoz F, Ismail M. Subclinical inflammatory reactions induced by phakic anterior chamber lenses for the correction of high myopia. *Ocular Immunology and Inflammation* 1993;1:219-223.
31. Strobel J, Fechner PU. Nachuntersuchung von Iris-claw-Linsen in phaken, myopen Augen. In: Schott K, Freyler K, Jacobi KW, eds. 4 Kongress der Deutschen Gesellschaft für Intraokularlinsen-Implantation in Essen 1990. Heidelberg, Germany: Springer Verlag;1991:20.
32. Apple DJ, Brems RN, Park RB, Norman DK, Hansen SO, Tetz MR, Richards SC, Letchinger SD. Anterior chamber lenses. Part 1. Complications and pathology and review of designs. *J Cataract Refract Surg* 1987;13:157-174.
33. Zaldivar R, Davidorff JM, Oscherow S. Posterior chamber phakic intraocular lens for myopia of -8 to -19 diopters. *J Refract Surg* 1998;14:294-305.